Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy

Neuropharmacology

Volumn 48, Issue 5, 2005, Pages 658-672

  Valenzano, Kenneth J ^a   Tafesse, Laykea ^a   Lee, Gary ^a   Harrison, James E ^a   Boulet, Jamie M ^a   Gottshall, Susan L ^a   Mark, Lilly ^a   Pearson, Michelle S ^a   Miller, Wendy ^a   Shan, Shen ^a   Rabadi, Leyana ^b   Rotshteyn, Yakov ^b   Chaffer, Suzanne M ^a   Turchin, Paul I ^a   Elsemore, David A ^a   Toth, Mathew ^a   Koetzner, Lee ^a   Whiteside, Garth T ^a  

^a Purdue Pharma Discovery Research   (United States)

^b PURDUE PHARMA L P   (United States)

Author keywords

Anxiety; Cannabinoid; Catalepsy; CB2; GW405833; Incisional pain; Inflammatory pain; Neuropathic pain; Pharmacokinetics; Radioligand binding; Rotarod

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID RECEPTOR AGONIST; CYCLIC AMP; GW 405833; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; ATAXIA; CATALEPSY; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HYPERALGESIA; INFLAMMATION; MALE; NEUROPATHIC PAIN; NONHUMAN; PAIN; PHYSIOLOGY; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SEDATION;

EID: 20144388149     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.12.008     Document Type: Article

References (41)

1. S.K. Bhattacharya, and G. Das Gupta Central modulation of peripheral inflammation Indian J. Exp. Biol. 26 1988 77 84
2. T.J. Brennan, E.P. Vandermeulen, and G.F. Gebhart Characterization of a rat model of incisional pain Pain 64 1996 493 501
3. N.E. Buckley, K.L. McCoy, E. Mezey, T. Bonner, A. Zimmer, C.C. Felder, M. Glass, and A. Zimmer Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor Eur. J. Pharmacol. 396 2000 141 149
4. V. Chapman, and D.P. Finn Analgesic effects of cannabinoids: sites and mechanisms of action Rev. Analg. 7 2003 25 39
5. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
6. N. Clayton, F.H. Marshall, C. Bountra, and C.T. O'Shaughnessy CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain Pain 96 2002 253 260
7. F.E. D'Amour, and D.L. Smith A method for determining loss of pain sensation J. Pharmacol. Exp. Ther. 72 1941 74 79
8. W.A. Devane, L. Hanuš, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
9. N.W. Dunham, and T.S. Miya A note on a simple apparatus for detecting neurological deficit in rats and mice J. Am. Pharm. Assoc. 46 1957 208 209
10. C.C. Felder, K.E. Joyce, E.M. Briley, J. Mansouri, K. Mackie, O. Blond, Y. Lai, A.L. Ma, and R.L. Mitchell Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors Mol. Pharmacol. 48 1995 443 450
11. A. Fox, A. Kesingland, C. Gentry, K. McNair, S. Patel, L. Urban, and I. James The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain Pain 92 2001 91 100
12. S. Galiegue, S. Mary, J. Marchand, D. Dussossoy, D. Carriere, P. Carayon, M. Bouaboula, D. Shire, G. Le Fur, and P. Caselas Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur. J. Biochem. 232 1995 54 61
13. M. Gallant, C. Dufresne, Y. Gareau, D. Guay, Y. Leblanc, P. Prasit, C. Rochette, N. Sawyer, D.M. Slipetz, N. Tremblay, K.M. Metters, and M. Labelle New class of potent ligands for the human peripheral cannabinoid receptor Bioorg. Med. Chem. Lett. 6 1996 2263 2268
14. S.J. Govaerts, E. Hermans, and D.M. Lambert Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors Eur. J. Pharm. Sci. 23 2004 233 243
15. A. Green, C. O'Shaughnessy, G. Disney, and F. Marshall Reporter assays for human cannabinoid CB1 and CB2 receptors for the identification of novel agonists Br. J. Pharmacol. 126 1999 112P
16. J. Haller, B. Varga, C. Ledent, and T.F. Freund CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents Behav. Pharmacol. 15 2004 299 304
17. L. Hanuš, A. Breuer, S. Tchilibon, S. Shiloah, D. Goldenberg, M. Horowitz, R.G. Pertwee, R.A. Ross, R. Mechoulam, and E. Fride HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor Proc. Natl Acad. Sci. U.S.A. 96 1999 14228 14233
18. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam, and R.G. Pertwee Classification of cannabinoid receptors Pharmacol. Rev. 54 2002 161 202
19. M.M. Ibrahim, H. Deng, A. Zvonok, D.A. Cockayne, J. Kwan, H.P. Mata, T.W. Vanderah, J. Lai, F. Porreca, A. Makriyannis, and T.P. Malan Jr. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS Proc. Natl Acad. Sci. U.S.A. 100 2003 10529 10533
20. B.J. Jones, and D.J. Roberts The quantitative measurement of motor inco-ordination in naïve mice using an accelerating rotarod J. Pharm. Pharmacol. 20 1968 302 304
21. S.H. Kim, and J.M. Chung An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat Pain 50 1992 355 363
22. 2 cannabinoid receptor-mediated peripheral antinociception Pain 93 2001 239 245
23. T.P. Malan Jr., M.M. Ibrahim, J. Lai, T.W. Vanderah, A. Makriyannis, and F. Porreca CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr. Opin. Pharmacol. 3 2003 62 67
24. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
25. S. Munro, K.L. Thomas, and M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61 65
26. A.G. Nackley, A. Makriyannis, and A.G. Hohmann Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation Neuroscience 119 2003 747 757
27. K. Njung'e, and S.L. Handley Evaluation of marble-burying behavior as a model of anxiety Pharmacol. Biochem. Behav. 38 1990 63 67
28. H.J. Patel, M.A. Birrell, N. Crispino, D.J. Hele, P. Venkatesan, P.J. Barnes, M.H. Yacoub, and M.G. Belvisi Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation Br. J. Pharmacol. 140 2003 261 268
29. A. Quartilho, H.P. Mata, M.M. Ibrahim, T.W. Vanderah, F. Porreca, A. Makriyannis, and T.P. Malan Jr. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors Anesthesiology 99 2003 955 960
30. R.A. Ross, A.A. Coutts, S.M. McFarlane, S. Anavi-Goffer, A.J. Irving, R.G. Pertwee, D.J. MacEwan, and R.H. Scott Neuropharmacology 40 2001 221 232
31. D.A. Scott, C.E. Wright, and J.A. Angus Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat Pain 109 2004 124 131
32. Z. Seltzer, R. Dubner, and Y. Shir A novel behavioral model of neuropathic pain disorder produced in rats by partial sciatic nerve injury Pain 43 1990 450 456
33. 2 receptors in anaesthetized rats Neuropharmacology 45 2003 404 411
34. L. Uriguen, S. Perez-Rial, C. Ledent, T. Palomo, and J. Manzanares Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors Neuropharmacology 46 2004 966 973
35. K.J. Valenzano, W.S. Miller, Z. Chen, S. Shan, G. Crumley, S.F. Victory, E. Davies, J.C. Huang, N. Allie, S.J. Nolan, Y. Rotstheyn, D.J. Kyle, and K. Broglé DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza- spiro[4.5]dec-3-yl]-acetic acid), a peripherally-acting mu agonist with analgesic activity: 1. In vitro pharmacological characterization and pharmacokinetic properties J. Pharmacol. Exp. Ther. 310 2004 783 792
36. L. Walter, A. Franklin, A. Witting, C. Wade, Y. Xie, G. Kunos, K. Mackie, and N. Stella Nonpsychotropic cannabinoid receptors regulate microglial cell migration J. Neurosci. 23 2003 1398 1405
37. L. Walter, and N. Stella Cannabinoids and neuroinflammation Br. J. Pharmacol. 141 2004 775 785
38. J. Wieseler-Frank, S.F. Maier, and L.R. Watkins Glial activation and pathological pain Neurochem. Int. 45 2004 389 395
39. G.T. Whiteside, J. Harrison, J. Boulet, L. Mark, M. Pearson, S. Gottshall, and K. Walker Pharmacological characterisation of a rat model of incisional pain Br. J. Pharmacol. 141 2004 85 91
40. G. Woolfe, and A.D. MacDonald The evaluation of the analgesic action of pethidine hydrochloride (Demerol) J. Pharmacol. Exp. Ther. 80 1944 300 307
41. J. Zhang, C. Hoffert, H.K. Vu, T. Groblewski, S. Ahmad, and D. O'Donnell Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models Eur. J. Neurosci. 17 2003 2750 2754